Comments
South Korea’s Daewoong Pharmaceutical Co is collaborating with Mankind Pharma to conduct Phase I clinical trials on a long-acting intramuscular formulation of Niclosamide, to evaluate its use in treating Covid-19.
The early-stage human trial is designed to investigate the new formulation based on encouraging preclinical evidence in the treatment of the virus, a note from the company said.
Niclosamide (DWRX2003) is a deworming medicine, but the new formulation is expected to avoid the downside of an oral administration.
The company said that in vitro (or in lab settings ) , “Niclosamide was found to be 40, 26 & 15 times more potent than Remdesivir, Chloroquine & Ciclesonide respectively for its anti-viral action against SARS-CoV-2 virus.”
Besides, the injectable intramuscular (IM) formulation of Niclosamide successfully removed the virus from lungs in animal tests, thereby countering viral infection, besides preventing cytokine storm which is the major cause of mortality in moderate to severe cases of Covid-19, the company said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.